R2810-ONC-1788
24 Nov 2020
Trial Summary
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).
Acronym:
R2810-ONC-1788
ACTRN/NCT /ethics:
NCT03969004
Scientific title:
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Sponsor / Cooperative group:
ICON / Regeneron
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Cutaneous Squamous Cell Carcinoma |
| Cancer Stage | All stages |
| Anticipated Start Date | 2019-06-04 |
| Anticipated End Date | 2026-02-11 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Anne Taylor |
| Recruitment Status | Recruiting |